Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with heart failure: Comparison with enalapril

被引：0
|
作者：
Abassi, ZA
Zeid, S
Yahia, A
Winaver, J
Hoffman, A
机构：
[1] Rambam Med Ctr, Haifa, Israel
[2] Technion Israel Inst Technol, Fac Med, Dept Physiol & Biophys, Haifa, Israel
来源：
AMERICAN JOURNAL OF HYPERTENSION | 2003年 / 16卷 / 05期
关键词：
omapatrilat; cardiac hypertrophy; renal function;
D O I：
10.1016/S0895-7061(03)00288-7
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
P123
引用
收藏
页码：84A / 84A
页数：1
相关论文
共 50 条
  • [21] Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in rat
    Kubota, E
    Dean, RG
    Hubner, RA
    Johnston, CI
    Casley, DJ
    Burrell, LM
    JOURNAL OF HYPERTENSION, 2002, 20 : S247 - S247
  • [22] Vasopeptidase Inhibitor,Omapatrilat, Enhances Cardiac Positive Inotropic and Lusitropic Responses to Dobutamine and Exercise in Heart Failure: Assessment by Pressure-Volume Analysis
    Hasegawa, Hiroshi
    Cheng, Heng-Jie
    Morimoto, Atsushi
    Little, William C.
    Cheng, Che Ping
    CIRCULATION, 2013, 128 (22)
  • [23] Effects of omapatrilat and lisinopril on renal function in patients with heart failure
    Rouleau, JL
    Pfeifer, MA
    Stewart, DJ
    Kerut, EK
    Porter, CB
    Parker, JO
    Smith, LK
    Proulx, G
    Qian, C
    Block, AJ
    CIRCULATION, 2000, 102 (18) : 533 - 533
  • [24] Vasopeptidase inhibition with omapatrilat in chronic heart failure: Acute and long-term hemodynamic and neurohumoral effects
    McClean, DR
    Ikram, H
    Mehta, S
    Heywood, JT
    Rousseau, MF
    Niederman, AL
    Sequeira, RF
    Fleck, E
    Singh, SN
    Coutu, B
    Hanrath, P
    Komajda, M
    Bryson, CC
    Qian, CL
    Hanyok, JJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (12) : 2034 - 2041
  • [25] Anti-apoptotic effect of the vasopeptidase inhibitor omapatrilat in rats with acute myocardial infarction
    El Mokhtari, NE
    Meissner, A
    Reinecke, A
    Krueger, D
    Lins, M
    Tiroke, A
    Simon, R
    EUROPEAN HEART JOURNAL, 2002, 23 : 203 - 203
  • [26] Natriuretic peptides in chronic stable heart failure patients treated with omapatrilat, a vasopeptidase inhibitor: The IMPRESS neurohormone substudy.
    Sheth, T
    Parker, T
    Block, A
    Qian, CL
    Rouleau, J
    CIRCULATION, 2001, 104 (17) : 762 - 762
  • [27] The actions of omapatrilat, vasopeptidase inhibitor (VPI), on cardiac hypertrophy and brain natriuretic peptide (BNP) concentration in spontaneously hypertensive rats
    Wei, CM
    Dong, YF
    Lin, RX
    FASEB JOURNAL, 2002, 16 (05): : A928 - A928
  • [28] Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial (vol 356, pg 615, 2000)
    Rouleau, JL
    LANCET, 2000, 356 (9243): : 1774 - 1774
  • [29] Effect of vasopeptidase inhibition with omapatrilat in a canine model of tachycardia-induced heart failure
    Holzgrefe, HH
    Arthur, SR
    Powell, JR
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 234A - 234A
  • [30] Comparative effects of a vasopeptidase inhibitor vs. an angiotensin convertin enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure
    Nathalie Lapointe
    James N. Tsoporis
    Thomas G. Parker
    Charles Blais
    Albert Adam
    Dominique Rouleau
    Graham Slaughter
    Robert Clément
    Christian F. Deschepper
    Jean L. Rouleau
    Molecular and Cellular Biochemistry, 2003, 254 : 235 - 245
12345